Dabigatran etexilate is an anticoagulant, i.e., it prevents blood clotting and effectively reduces the risk of thrombosis. It is generally used in patients with a history of cerebral infarction and transient ischemic attacks, as well as a history of systemic embolism. Patients such as these, who are often at high risk for exacerbation and recurrence of cerebral infarction, can be treated with dabigatranate if necessary. However, it must also be clear that the amount of dabigatranate and the number of oral doses per day need to be determined on a case-by-case basis, and that there is also a risk of bleeding and renal insufficiency, and that it is best to apply it under the guidance of a physician. The usual initial dose is 300 mg twice daily, but patients with a high risk of bleeding are advised to take 220 g orally twice daily, and therefore need to be treated on a case-by-case basis.